Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802275 | 0.92 | ADRA1A (0.48) | ADRA1ATAAR1MTNR1AMTNR1BAPLNR | |
| SCHEMBL8275708 | 0.88 | ADRA1A (0.46) | ADRA1ATAAR1MTNR1AMTNR1BAPLNR | |
| SCHEMBL10607590 | 0.85 | ALDH1A1 (0.45) | ADRA1ATAAR1MTNR1AMTNR1BAPLNR | |
| SCHEMBL16952197 | 0.81 | KDM4E (0.44) | ADRA1ATAAR1MTNR1AMTNR1BPOLB | |
| SCHEMBL5154843 | 0.80 | ADRA1A (0.70) | ADRA1ATAAR1MTNR1AMTNR1BIDO1 | |
| SCHEMBL9921244 | 0.80 | TAAR1 (0.46) | ADRA1ATAAR1APLNRALOX5POLB | |
| SCHEMBL9917312 | 0.80 | KMT2A (0.48) | ADRA1ATAAR1APLNRALOX5POLB | |
| SCHEMBL6123805 | 0.80 | APLNR (0.61) | ADRA1ATAAR1APLNRALOX5 | |
| SCHEMBL23575258 | 0.80 | ESR1 (0.47) | ADRA1ATAAR1MTNR1AMTNR1BAPLNR | |
| SCHEMBL13039484 | 0.80 | ADRA1A (0.46) | ADRA1ATAAR1APLNRIDO1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220010436-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | SEKISUI CHEMICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11193212-B2 | Synthetic method and synthetic system | SEKISUI CHEMICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11193212-B2 | Synthetic method and synthetic system | HCCS, CYP11B2, COX14 | ADRA1A 3704/4885TAAR1 132/4885MTNR1A 4756/4885 |
| US-20220010436-A1 | SYNTHETIC METHOD AND SYNTHETIC SYSTEM | HCCS, CYP11B2, COX14 | ADRA1A 3704/4885TAAR1 132/4885MTNR1A 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.